Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer

  • Álvarez-Fernández, Mónica
  • Sanz-Flores, María
  • Sanz-Castillo, Belén
  • Salazar Roa, María
  • Partida, David
  • Zapatero-Solana, Elisabet
  • Ali, Raza
  • Manchado, Eusebio
  • Lowe, Scott
  • VanArsdale, Todd
  • Shields, David
  • Caldas, Carlos
  • Quintela-Fandino, Miguel
  • Malumbres, Marcos
PP2A is a major tumor suppressor whose inactivation is frequently found in a wide spectrum of human tumors. In particular, deletion or epigenetic silencing of genes encoding the B55 family of PP2A regulatory subunits is a common feature of breast cancer cells. A key player in the regulation of PP2A/B55 phosphatase complexes is the cell cycle kinase MASTL (also known as Greatwall). During cell division, inhibition of PP2A-B55 by MASTL is required to maintain the mitotic state, whereas inactivation of MASTL and PP2A reactivation is required for mitotic exit. Despite its critical role in cell cycle progression in multiple organisms, its relevance as a therapeutic target in human cancer and its dependence of PP2A activity is mostly unknown. Here we show that MASTL overexpression predicts poor survival and shows prognostic value in breast cancer patients. MASTL knockdown or knockout using RNA interference or CRISPR/Cas9 systems impairs proliferation of a subset of breast cancer cells. The proliferative function of MASTL in these tumor cells requires its kinase activity and the presence of PP2A-B55 complexes. By using a new inducible CRISPR/Cas9 system in breast cancer cells, we show that genetic ablation of MASTL displays a significant therapeutic effect in vivo. All together, these data suggest that the PP2A inhibitory kinase MASTL may have both prognostic and therapeutic value in human breast cancer.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Thrombocytopenia-associated mutations in Ser/Thr kinase MASTL deregulate actin cytoskeletal dynamics in platelets

  • Hurtado, Begoña
  • Trakala, Marianna
  • Ximénez-Embún, Pilar
  • El Bakkali, Aicha
  • Partida, David
  • Sanz-Castillo, Belén
  • Álvarez-Fernández, Mónica
  • Maroto, María
  • Sánchez-Martínez, Ruth
  • Martínez, Lola
  • Redondo-Muñoz, Javier
  • García de Frutos, Pablo
  • Malumbres, Marcos
MASTL, a Ser/Thr kinase that inhibits PP2A-B55 complexes during mitosis, is mutated in autosomal dominant thrombocytopenia. However, the connections between the cell-cycle machinery and this human disease remain unexplored. We report here that, whereas Mastl ablation in megakaryocytes prevented proper maturation of these cells, mice carrying the thrombocytopenia-associated mutation developed thrombocytopenia as a consequence of aberrant activation and survival of platelets. Activation of mutant platelets was characterized by hyperstabilized pseudopods mimicking the effect of PP2A inhibition and actin polymerization defects. These aberrations were accompanied by abnormal hyperphosphorylation of multiple components of the actin cytoskeleton and were rescued both in vitro and in vivo by inhibiting upstream kinases such as PKA, PKC, or AMPK. These data reveal an unexpected role of Mastl in actin cytoskeletal dynamics in postmitotic cells and suggest that the thrombocytopenia-associated mutation in MASTL is a pathogenic dominant mutation that mimics decreased PP2A activity resulting in altered phosphorylation of cytoskeletal regulatory pathways., BH and RSM were supported by the Juan de la Cierva Programme of the Spanish Ministry of Economy and Competitiveness (MINECO). MT was supported by the Foundation La Caixa. AEB was supported by the Programa de Empleo Juvenil, Comunidad de Madrid. MAF received a young investigator grant from MINECO (SAF2014-60442-JIN, cofinanced by FEDER funds). PGDF was supported by the Fundació la Marató de TV3 (projects 080121 and 20153031). JM was supported by the Ramon y Cajal Programme (MINECO; RYC-2012-10651). The laboratory of MM is supported by grants from MINECO (SAF2015-69920-R); the Programa iLUNG from the Comunidad de Madrid (B2017/BMD-3884); and Worldwide Cancer Research (15-0278). CNIO is a Severo Ochoa Center of Excellence (MINECO award SEV-2015-0510)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The MASTL/PP2A cell cycle kinase-phosphatase module restrains PI3K-Akt activity in an mTORC1-dependent manner

  • Sanz-Castillo, Belén
  • Hurtado, Begoña
  • Vara-Ciruelos, Diana
  • El Bakkali, Aicha
  • Hermida, Dario
  • Salvador-Barbero, Beatriz
  • Martínez-Alonso, Diego
  • González-Martínez, José
  • Santiveri, Clara
  • Campos-Olivas, Ramón
  • Ximénez de Embún, Pilar
  • Redondo-Muñoz, Javier
  • Álvarez-Fernández, Mónica
  • Malumbres, Marcos
The AKT-mTOR pathway is a central regulator of cell growth and metabolism. Upon sustained mTOR activity, AKT activity is attenuated by a feedback loop that restrains upstream signaling. However, how cells control the signals that limit AKT activity is not fully understood. Here, we show that MASTL/Greatwall, a cell cycle kinase that supports mitosis by phosphorylating the PP2A/B55 inhibitors ENSA/ARPP19, inhibits PI3K-AKT activity by sustaining mTORC1- and S6K1-dependent phosphorylation of IRS1 and GRB10. Genetic depletion of MASTL results in an inefficient feedback loop and AKT hyperactivity. These defects are rescued by the expression of phosphomimetic ENSA/ARPP19 or inhibition of PP2A/B55 phosphatases. MASTL is directly phosphorylated by mTORC1, thereby limiting the PP2A/B55-dependent dephosphorylation of IRS1 and GRB10 downstream of mTORC1. Downregulation of MASTL results in increased glucose uptake in vitro and increased glucose tolerance in adult mice, suggesting the relevance of the MASTL-PP2A/B55 kinase-phosphatase module in controlling AKT and maintaining metabolic homeostasis., BS‐C was supported by Foundation la Caixa, and AEB was funded by Comunidad de Madrid. MÁ‐F was supported by a young investigator grant from the Spanish Ministry of Economy and Competitiveness (MINECO; SAF2014‐60442‐JIN; co‐financed by FEDER funds). The Cell Division and Cancer lab of the CNIO is supported by grants from the MICIU (RTI2018‐095582‐B‐I00), Red de Excelencia iDIFFER (RED2018‐102723‐T), Comunidad de Madrid (B2017/BMD‐3884), and Worldwide Cancer Research (WCR‐20‐0155)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma

  • Salvador-Barbero, Beatriz
  • Álvarez-Fernández, Mónica
  • Zapatero-Solana, Elisabet
  • Bakkali, Aicha El
  • Camino Menéndez, María del
  • López-Casas, Pedro P.
  • Domenico, Tomas Di
  • Xie, Tao
  • VanArsdale, Todd
  • Shields, David J.
  • Hidalgo, Manuel M.
  • Malumbres, Marcos
Inhibition of the cell-cycle kinases CDK4 and CDK6 is now part of the standard treatment in advanced breast cancer. CDK4/6 inhibitors, however, are not expected to cooperate with DNA-damaging or antimitotic chemotherapies as the former prevent cell-cycle entry, thus interfering with S-phase- or mitosis-targeting agents. Here, we report that sequential administration of CDK4/6 inhibitors after taxanes cooperates to prevent cellular proliferation in pancreatic ductal adenocarcinoma (PDAC) cells, patient-derived xenografts, and genetically engineered mice with Kras G12V and Cdkn2a-null mutations frequently observed in PDAC. This effect correlates with the repressive activity of CDK4/6 inhibitors on homologous recombination proteins required for the recovery from chromosomal damage. CDK4/6 inhibitors also prevent recovery from multiple DNA-damaging agents, suggesting broad applicability for their sequential administration after available chemotherapeutic agents., M.Á.-F. received young investigator grants from MINECO (SAF2014-60442-JIN, cofinanced by FEDER funds) and the Asociación Española contra el Cancer (AECC). The laboratory of M.M. is supported by grants from MICIU [SAF2015-69920-R and RTI2018-095582-B-I00 (AEI-MICIU/FEDER, UE)], and the iLUNG program from the Comunidad de Madrid (B2017/BMD-3884). CNIO is a Severo Ochoa Center of Excellence (MINECO award SEV-2015-0510)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition

  • Álvarez-Fernández, Mónica
  • Malumbres, Marcos
Inhibiting the cell-cycle kinases CDK4 and CDK6 results in significant therapeutic effect in patients with advanced hormone-positive breast cancer. The efficacy of this strategy is, however, limited by innate or acquired resistance mechanisms and its application to other tumor types is still uncertain. Here, through an integrative analysis of sensitivity and resistance mechanisms, we discuss the use of CDK4/6 inhibitors in combination with available targeted therapies, immunotherapy, or classical chemotherapy with the aim of improving future therapeutic uses of CDK4/6 inhibition in a variety of cancers., MAF received young investigator grants from MINECO (SAF2014-60442-JIN, co-financed by FEDER funds) and the Asociación Española contra el Cancer (AECC). The laboratory of M.M. is supported by grants from AEI-MICIU/FEDER (RTI2018-095582-B-I00 and RED2018-102723-T), and the iLUNG program from the Comunidad de Madrid (B2017/BMD-3884). CNIO is a Severo Ochoa Center of Excellence (MINECO award SEV-2015-0510)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Transient exposure to miR‐203 enhances the differentiation capacity of established pluripotent stem cells

  • Salazar‐Roa, María
  • Trakala, Marianna
  • Álvarez-Fernández, Mónica
  • Valdés‐Mora, Fátima
  • Zhong, Cuiqing
  • Muñoz, Jaime
  • Yu, Yang
  • Peters, Timothy J.
  • Graña‐Castro, Osvaldo
  • Serrano, Rosa
  • Zapatero-Solana, Elisabet
  • Abad, María
  • Bueno, María José
  • Gómez de Cedrón, Marta
  • Fernández-Piqueras, José
  • Serrano, Manuel
  • Blasco, María A.
  • Wang, Da‐Zhi
  • Clark, Susan J.
  • Izpisua‐Belmonte, Juan Carlos
  • Ortega, Sagrario
  • Malumbres, Marcos
Full differentiation potential along with self‐renewal capacity is a major property of pluripotent stem cells (PSCs). However, the differentiation capacity frequently decreases during expansion of PSCs in vitro. We show here that transient exposure to a single microRNA, expressed at early stages during normal development, improves the differentiation capacity of already‐established murine and human PSCs. Short exposure to miR‐203 in PSCs (miPSCs) induces a transient expression of 2C markers that later results in expanded differentiation potency to multiple lineages, as well as improved efficiency in tetraploid complementation and human–mouse interspecies chimerism assays. Mechanistically, these effects are at least partially mediated by direct repression of de novo DNA methyltransferases Dnmt3a and Dnmt3b, leading to transient and reversible erasure of DNA methylation. These data support the use of transient exposure to miR‐203 as a versatile method to reset the epigenetic memory in PSCs, and improve their effectiveness in regenerative medicine., M.S.R. was supported by the Asociación Española contra el Cáncer (AECC; 2012 AIOA120833SALA and 2018 INVES18005SALA) and a Juan de la Cierva contract from the Ministry of Science, Innovation and Universities (MICIU). M.T. was supported by Fundación La Caixa. M.A.F. was supported by MICIU (SAF2014‐60442‐JIN). J.F.P. was funded by MICIU (RTI2018‐093330‐B/FEDER‐EU), Ramón Areces Foundation (CIVP19S7917), CAM (B2017/BMD‐3778), and AECC (2018, PROYE18054PIRI). F.V.M was supported by the National Breast Cancer Foundation/Cure Cancer Australia Foundation Postdoctoral Training Fellow. Work in S.J.C laboratory was supported by the National Health and Medical Research Council (NHMRC 1063560). M.A.B. laboratory is funded by SAF2013‐45111‐R from MICIU, Fundación Botín and Banco Santander, and Worldwide Cancer Research (WCR16‐1177). Work in S.O. laboratory was funded by MICIU grant (SAF2013‐44866‐R). Work in the M.M. laboratory was supported by grants from the MICIU (RTI2018‐095582‐B‐I00, RED2018‐102723‐T, and SAF2017‐92729‐EXP), and the iLUNG Programme (B2017/BMD‐3884) from the Comunidad de Madrid. The CNIO is a Severo Ochoa Centers of Excellence (MICIU award SEV‐2015‐0510)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer

  • Álvarez-Fernández, Mónica
  • Sanz-Flores, María
  • Sanz-Castillo, Belén
  • Salazar-Roa, María
  • Partida, David
  • Zapatero-Solana, Elisabet
  • Raza Ali, H.
  • Manchado, Eusebio
  • Lowe, Scott
  • VanArsdale, Todd
  • Shields, David
  • Caldas, Carlos
  • Quintela-Fandino, Miguel
  • Malumbres, Marcos
PP2A is a major tumor suppressor whose inactivation is frequently found in a wide spectrum of human tumors. In particular, deletion or epigenetic silencing of genes encoding the B55 family of PP2A regulatory subunits is a common feature of breast cancer cells. A key player in the regulation of PP2A/B55 phosphatase complexes is the cell cycle kinase MASTL (also known as Greatwall). During cell division, inhibition of PP2A-B55 by MASTL is required to maintain the mitotic state, whereas inactivation of MASTL and PP2A reactivation is required for mitotic exit. Despite its critical role in cell cycle progression in multiple organisms, its relevance as a therapeutic target in human cancer and its dependence of PP2A activity is mostly unknown. Here we show that MASTL overexpression predicts poor survival and shows prognostic value in breast cancer patients. MASTL knockdown or knockout using RNA interference or CRISPR/Cas9 systems impairs proliferation of a subset of breast cancer cells. The proliferative function of MASTL in these tumor cells requires its kinase activity and the presence of PP2A-B55 complexes. By using a new inducible CRISPR/Cas9 system in breast cancer cells, we show that genetic ablation of MASTL displays a significant therapeutic effect in vivo. All together, these data suggest that the PP2A inhibitory kinase MASTL may have both prognostic and therapeutic value in human breast cancer., M.A.F. was supported by a young investigator grant from the Spanish Ministry of Economy and Competitiveness (MINECO; SAF2014-60442-JIN; co-financed by FEDER funds). M.S.F. was supported by a fellowship from the Ministry of Educación, Cultura y Deporte, and B.S.-C. was supported by Fundación La Caixa. The research described in the manuscript was funded in part by Pfizer. Work in the M.M. laboratory was supported by grants from the MINECO (SAF2012-38215), Consolider-Ingenio 2010 Programme (SAF2014-57791-REDC), Excellence Network CellSYS (BFU2014-52125-REDT), the OncoCycle Programme (S2010/BMD-2470) from the Comunidad de Madrid, Worldwide Cancer Research (WCR no. 15-0278), and the European Union Seventh Framework Programme (MitoSys project; HEALTH-F5-2010-241548)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

An E2F7-dependent transcriptional program modulates DNA damage repair and genomic stability

  • Mitxelena, Jone
  • Apraiz, Aintzane
  • Vallejo-Rodríguez, Jon
  • García-Santisteban, Iraia
  • Fullaondo, Asier
  • Álvarez-Fernández, Mónica
  • Malumbres, Marcos
  • Zubiaga, Ana
The cellular response to DNA damage is essential for maintaining the integrity of the genome. Recent evidence has identified E2F7 as a key player in DNA damage-dependent transcriptional regulation of cell-cycle genes. However, the contribution of E2F7 to cellular responses upon genotoxic damage is still poorly defined. Here we show that E2F7 represses the expression of genes involved in the maintenance of genomic stability, both throughout the cell cycle and upon induction of DNA lesions that interfere with replication fork progression. Knockdown of E2F7 leads to a reduction in 53BP1 and FANCD2 foci and to fewer chromosomal aberrations following treatment with agents that cause interstrand crosslink (ICL) lesions but not upon ionizing radiation. Accordingly, E2F7-depleted cells exhibit enhanced cell-cycle re-entry and clonogenic survival after exposure to ICL-inducing agents. We further report that expression and functional activity of E2F7 are p53-independent in this context. Using a cell-based assay, we show that E2F7 restricts homologous recombination through the transcriptional repression of RAD51. Finally, we present evidence that downregulation of E2F7 confers an increased resistance to chemotherapy in recombination-deficient cells. Taken together, our results reveal an E2F7-dependent transcriptional program that contributes to the regulation of DNA repair and genomic integrity., This work was supported by grants from the Spanish Ministry [SAF2012-33551 and SAF2015-67562-R, co-financed by FEDER funds, and SAF2014-57791-REDC], the Basque Government [IT634-13 and KK-2015/89], and the University of the Basque Country UPV/EHU [UFI11/20] to AMZ; and grants from the Spanish Ministry [SAF2015-69920-R], and Worldwide Cancer Research [15-0278] to MM. JM was recipient of a Basque Government fellowship for graduate studies and JVR is recipient of a UPV/EHU fellowship for graduate studies. M.A.F. was supported by a young investigator grant from MINECO [SAF2014-60442-JIN; co-financed by FEDER funds]. Funding for open access charge: Spanish Ministry [SAF2015-67562-R, co-financed by FEDER funds]; Basque Government [IT634-13]., Peer reviewed